UroGen Pharma
URGN
105 hedge funds and large institutions have $328M invested in UroGen Pharma in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 18 reducing their positions, and 12 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 18
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
32% more capital invested
Capital invested by funds: $248M → $328M (+$79.7M)
12.29% more ownership
Funds ownership: 58.53% → 70.82% (+12%)
4% more funds holding
Funds holding: 101 → 105 (+4)
2% more call options, than puts
Call options by funds: $344K | Put options by funds: $336K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.8M |
| 2 |
RI
RTW Investments
New York
|
+$11.3M |
| 3 |
Morgan Stanley
New York
|
+$10.4M |
| 4 |
BlackRock
New York
|
+$6.77M |
| 5 |
Millennium Management
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.21M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$3.11M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.39M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.69M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.69M |
URGN Hedge Fund Activity: Q4 2023 in Review
105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2023, worth a combined $328M — up 32% from $248M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new URGN positions and 12 closed out — a net gain of 4 holders — while 50 added to existing stakes and 18 trimmed.
The largest buyer was RA Capital Management, adding an estimated $20.8M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $5.21M sold.
- 105 institutional investors held UroGen Pharma (URGN) as of Q4 2023, up from 101 in Q3 2023.
- Funds reported $328M of UroGen Pharma stock for Q4 2023, up 32% quarter-over-quarter.
- 16 funds opened new UroGen Pharma positions in Q4 2023 and 12 closed out, a net change of +4 holders.
- The largest UroGen Pharma buyer in Q4 2023 was RA Capital Management, an estimated $20.8M added.
- The largest UroGen Pharma seller in Q4 2023 was Soleus Capital Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q4 2023.